Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in myeloproliferative neoplasms
- Trial result
Myeloproliferative neoplasms
Ruxolitinib (JAK1/2 inhibitor) Loses SVR35/TSS50 Ground When Early Cytopenias Emerge in MF
Ruxolitinib is an oral JAK1/2 inhibitor approved for myelofibrosis (MF), but dose intensity is often constrained by anemia and thrombocytopenia. In this post hoc analysis of the Phase 3 SIMPLIFY-1 trial…
NCT01969838 - Trial result Spotlight
Myeloproliferative neoplasms
Navitoclax (BCL-2/BCL-XL inhibitor) + ruxolitinib doubles Week-24 spleen responses in frontline myelofibrosis, with major cytopenias
Navitoclax (NAV), an oral BCL-2/BCL-XL inhibitor that can potentiate apoptosis but predictably worsens platelet counts via BCL-XL inhibition, was combined with the JAK1/2 inhibitor ruxolitinib (RUX) in the Phase 3…
NCT04472598 - Trial result
Myeloproliferative neoplasms
Imetelstat (telomerase inhibitor) doubles mOS vs real‑world BAT after ruxolitinib in R/R myelofibrosis
Imetelstat (IME) is a first-in-class telomerase inhibitor evaluated in IMbark (Phase 2; NCT02426086) in intermediate‑2/high‑risk myelofibrosis after Janus kinase inhibitor (JAKi) relapse/refractoriness. In this…
NCT02426086 - Trial result
Myeloproliferative neoplasms
DISC-0974 (anti-hemojuvelin; hepcidin-lowering) drives 50–71% anemia responses in Phase 2 myelofibrosis
DISC-0974 is a first-in-class monoclonal antibody that blocks hemojuvelin (HJV) to suppress BMP-pathway–driven hepcidin and improve iron availability for erythropoiesis. In the US open-label Phase 2 RALLY-MF study…
NCT05320198 - Trial result
Myeloproliferative neoplasms
Bomedemstat (LSD1 inhibitor) shrinks spleen and improves fibrosis markers in JAKi-refractory myelofibrosis
Bomedemstat (IMG-7289/MK-3543) is an oral, irreversible lysine-specific demethylase 1 (LSD1/KDM1A) inhibitor evaluated in an open-label Phase 1/2 study in myelofibrosis patients refractory/resistant to, inadequately…
NCT03136185 - Trial result
Myeloproliferative neoplasms
Ruxolitinib + Abemaciclib (CDK4/6) Shows 44% SVR35 in Rux-Inadequate-Response Myelofibrosis
Ruxolitinib (a JAK1/2 inhibitor) was combined with abemaciclib (an oral CDK4/6 inhibitor that blocks G1/S cell-cycle progression) in a Phase I 3+3 dose-escalation study in previously treated myelofibrosis with…
NCT05714072 - New trial Spotlight
Myeloproliferative neoplasms
Phase 1 PRT12396 mutant-selective JAK2V617F inhibitor (allosteric JH2 “pseudokinase” inhibitor) in PV/MF
Prelude Therapeutics is running a first-in-human, open-label, multi-center Phase 1 dose-escalation/expansion study testing PRT12396, an oral, twice-daily small molecule designed to selectively inhibit the JAK2 V617F…
NCT07469891 First-in-human - New trial
Myeloproliferative neoplasms
Phase II Pacritinib JAK2/FLT3 inhibitor bridge in accelerated/blast-phase MPN
University of Washington is testing pacritinib (a JAK2/FLT3 inhibitor) layered onto standard hypomethylating agents (azacitidine or decitabine/cedazuridine) to raise transplant eligibility in accelerated/blast-phase…
NCT07148947 Exploratory - Trial result Spotlight
Myeloproliferative neoplasms
Avapritinib (KIT D816V) Beats Midostaurin/Cladribine on OS in AdvSM
Avapritinib, a selective KIT D816V inhibitor, was compared via IPTW-adjusted external controls to midostaurin (multikinase/KIT) or cladribine (purine analog) using EXPLORER/PATHFINDER trial patients (n=176) versus…
- New trial
Myeloproliferative neoplasms
Phase III Trial of Benralizumab in Hypereosinophilic Syndrome
A multicentre, randomised, double-blind, placebo-controlled study will evaluate benralizumab versus placebo over a 24-week period, with an open-label extension for eligible HES patients. AstraZeneca is assessing…
NCT04191304
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.